Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck and Eisai's Phase 3 LEAP-012 trial shows that the combination of KEYTRUDA and LENVIMA with TACE reduces the risk of disease progression or death by 34% in advanced liver cancer patients compared to TACE alone. These results were presented at the European Society for Medical Oncology Congress 2024.
September 16, 2024 | 6:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eisai's LENVIMA, when used with KEYTRUDA, shows significant efficacy in advanced liver cancer, which could strengthen its product portfolio and market presence.
The trial results highlight LENVIMA's effectiveness in combination therapy, potentially boosting Eisai's reputation and market share in oncology, which may positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80
POSITIVE IMPACT
Merck's KEYTRUDA, in combination with LENVIMA, shows promising results in reducing disease progression in advanced liver cancer, potentially boosting its market position.
The positive results from the Phase 3 trial of KEYTRUDA in combination with LENVIMA could enhance Merck's market position in oncology, likely leading to increased investor confidence and a potential short-term stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 80